Active Pharmaceutical Ingredients Global Market Analysis 2024


The Global Active Pharmaceutical Ingredients Market is projected to reach $285.34 billion by 2027, from a value of $175.39 billion in 2020, by registering a CAGR of 7.2% during the forecast period 2020 – 2027

SKU: ER1019 Category:
© Epson Research 2021
Share this infographic on
Published Year:
Forecast period:
Report Coverage:

Market Trends and analysis of the crucial market segments across North America, Europe, Asia Pacific and Rest of the World.

Report Format:

5 User License

$ 5,500

  • Access to Five users
  • Print upto 5 copies
  • PDF & Excel Formats

Corporate User License

$ 7,000

  • Unlimited users within company
  • Free Yearly update
  • PDF & Excel Formats

The Global Active Pharmaceutical Ingredients Market is projected to reach $285.34 billion by 2027, from a value of $175.39 billion in 2020, by registering a CAGR of 7.2% during the forecast period. Growing incidence of chronic diseases, increasing importance of generics, technological advancements in API manufacturing, increasing adoption of AI-based tools for drug discovery, raising adoption of organ-on-chip models in drug development, and rising uptake of biopharmaceuticals are the major factors propelling the growth of the market. However, huge manufacturing costs, unfavorable drug price control policies across various countries, and increasing penetration of counterfeit drugs are hampering market growth. Moreover, highly potent active pharmaceutical ingredients, emerging biosimilars market, launches of new drugs and biological products, and increasing investments in real-world evidence by pharmaceutical companies are creating ample opportunities across the globe.

Recent Developments

In April, 2020, Boehringer Ingelheim announced acquisition of Northern Biologics. By acquiring this company, Boehringer Ingelheim focuses on therapeutic antibodies for cancer, and strengthened its position in the stromal biology sector, which is an emerging area in immuno-oncology.

In August 2020, Pfizer Inc. announced a multi-year agreement with Gilead Sciences Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir supporting efforts to scale up the supply of the investigational treatment for COVID-19.

In January 2020, Merck announced its strategic collaboration for the oncology platform with Taiho Pharmaceutical Co, Ltd. and Taiho Pharmaceutical Co, Ltd, to expand its focus on small molecule inhibitors for cancer research.

In January 2020, Novartis (Switzerland) acquired Aspen’s Japanese operations to strengthen its position in the global generics and off-patent medicines market. Novartis also entered into a manufacturing and supply agreement with Aspen.

Competitive Landscape

AbbVie Inc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla, Inc, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc, Mylan N.V, Novartis International AG, Pfizer, Inc, Sanofi, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the major players in the global Active Pharmaceutical Ingredients market.


1 Summary
2 Market Overview
2.1 Abstract
2.2 Research Sources
2.3 Research Findings
2.4 Assumptions
3 Market Dynamics
3.1 Drivers & Opportunities
3.2 Restraints & Threats
3.3 Regulatory Affairs
3.4 Supplychain Analysis
3.5 PORTERS Analysis
4 Competitive Landscape
5 Active Pharmaceutical Ingredients Market by Business Mode
5.1 Captive Manufacturers
5.2 Merchant Manufacturers
6 Active Pharmaceutical Ingredients Market by Type of Drug
6.1 Prescription Drugs
6.2 Over-the-counter Drugs
7 Active Pharmaceutical Ingredients Market by Type of Synthesis
7.1 Biotech
7.1.1 Type Biosimilars Innovative Biotech APIs
7.1.2 Expression System Insect Expression Systems Mammalian Expression Systems Microbial Expression Systems Plant Expression Systems Yeast Expression Systems
7.2 Synthetic
7.2.1 Branded/Innovative
7.2.2 Generic
8 Active Pharmaceutical Ingredients Market by Therapeutic Application
8.1 Cardiovascular Disease
8.2 Communicable Diseases
8.3 Diabetes
8.4 Gastroenterology
8.5 Neurology
8.6 Oncology
8.7 Ophthalmology
8.8 Orthopedics
8.9 Pain Management
8.10 Pulmonology
8.11 Respiratory Diseases
8.12 Urology and Nephrology
8.13 Women’s Health
9 Active Pharmaceutical Ingredients Market by Product
9.1 Blood Factors
9.2 Cytokines
9.3 Fusion Proteins
9.4 Hormones
9.5 Monoclonal Antibodies
9.6 Therapeutic Enzymes
9.7 Vaccines
10 Active Pharmaceutical Ingredients Market by Regions
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Rest of the World
11 Company Profiles
11.1 AbbVie Inc
11.2 AstraZeneca
11.3 Boehringer Ingelheim
11.4 Bristol-Myers Squibb
11.5 Cipla, Inc
11.6 Dr. Reddy’s Laboratories Ltd
11.7 Eli Lilly and Company
11.8 F. Hoffmann-La Roche Ltd
11.9 GlaxoSmithKline plc
11.10 Merck & Co., Inc
11.11 Mylan N.V
11.12 Novartis International AG
11.13 Pfizer, Inc
11.14 Sanofi
11.15 Sun Pharmaceutical Industries Ltd
11.16 Teva Pharmaceutical Industries Ltd